On November 14, Moderna, Inc. fell 3.3% in After-Hours Trading to $216.0 per share, with turnover of $55.7341 million.
The move followed an analyst day update in which the company outlined its next growth phase, but investor sentiment remained cautious despite improved revenue growth expectations.
Moderna, Inc. said it expects total liquidity of about $9 billion by year-end, projects cash costs of about $4 billion in 2027 and roughly $4.0 billion to $4.5 billion annually from 2027 through 2030, and extended the maturity of its $1.5 billion Ares credit facility to 2031. The company also raised its revenue growth outlook to 15% to 25% and said infectious disease vaccine profitability should improve as development spending declines and manufacturing efficiency improves. Even so, recent market focus has remained on spending needs, execution pace, and mixed but still cautious options positioning, leaving the shares under pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments